TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03397225

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: The educational sessions and individual sessions including dietary management and physical activity advices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The educational sessions and individual sessions including dietary management and physical activity advices.
Study: NCT03213444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy with 5-FU isolated
Description: Patients submitted to adjuvant chemotherapy with 5-FU isolated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy with 5-FU associated with oxaliplatin
Description: Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
Study: NCT00764621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracellular contrast media (ECCM) MRI
Description: Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced CT
Description: Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
Study: NCT00963573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
Study: NCT03757858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotron RF-8
Description: Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotron RF-8
Description: Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotron RF-8
Description: Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermotron RF-8
Description: Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive cellular Immunotherapy
Description: Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive cellular Immunotherapy
Description: Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.
Study: NCT04512248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit and Stay Quit Monday Model
Description: Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT.
Study: NCT03757858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive cellular Immunotherapy
Description: Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
Study: NCT04190121

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prosure
Description: The study group will receive the dietary supplement preoperatively and for three months after the operation
Study: NCT01674218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
Study: NCT01175980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT01674218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
Study: NCT04607993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prone position ventilation technique
Description: 1. Inform the children's family members of the purpose and method of prone position ventilation~2. Assess the fixation of various catheters~3. Suspend feeding before placing prone position~4. Confirm the time to start prone position ventilation under the joint assessment of medical staff~5. Place the child in a prone position with the participation of researchers, doctors and nursing staff, with the child's head tilted to one side to avoid damage to the eyes and nose due to compression, and the arms are bent upward to form a W . Bend both lower limbs downward to form an M shape, and use a soft pillow cushion to measure the knee joints to avoid compression~6. The whole process ensures the smooth fixation of tracheal intubation and various catheters~7. Proper sedation during prone position ventilation to achieve good human-machine synchronization~8. At least 6-8 hours in prone position every day
Study: NCT03227887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two samples of saliva
Description: 1. Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~2. With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two samples of saliva
Description: 1. Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~2. With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation
Study: NCT01674218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
Study: NCT01382888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin 2,400 IU /ml Cutaneous Spray
Description: Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cutaneous Spray
Description: Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
Study: NCT01217294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided fascia iliaca block
Description: Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: spinal morphine
Description: Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
Study: NCT03816475

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance.
Study: NCT00629018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ autologous stem cell transplantation
Description: Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Marrow Stimulation
Description: Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC therapy
Description: In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
Study: NCT02561117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Administration once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Administration once daily
Study: NCT02608411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ197
Study: NCT01107691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amount of resistance offered in training
Description: to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amount of resistance offered in training
Description: to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
Study: NCT00652340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricoxib/erlotinib
Description: apricoxib: 100 mg tablets, 400mg/day~erlotinib: per package insert

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib/placebo
Description: erlotinib: per package insert~placebo: 100 mg tablets, 400 mg/day
Study: NCT02617797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Radiofrequency OFF
Description: Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
Study: NCT03227887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing behaviour
Description: Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing behaviour
Description: Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study of the food bolus
Description: 2 tests:~1. Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~2. The bolus will be analysed visually

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study of the food bolus
Description: 2 tests:~1. Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~2. The bolus will be analysed visually

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthfeel
Description: Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthfeel
Description: Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
Study: NCT02130063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron isomaltoside 1000 (Monofer®)
Study: NCT02779972

Intervention type: OTHER
Intervention: Echo stress test
Description: Echo stress test

Intervention type: OTHER
Intervention: Echo stress test
Description: Echo stress test

Intervention type: OTHER
Intervention: Echo stress test
Description: Echo stress test
Study: NCT01760772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-9
Description: Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: Constant infusion of GLP-1 at 0.3 pmol/kg/min

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Constant infusion
Study: NCT02216448

Intervention type: OTHER
Group type: OTHER
Intervention: Training knee simulator
Description: Training in a lab on a virtual reality knee arthroscopy simulator

Intervention type: OTHER
Group type: OTHER
Intervention: OR Training
Description: Training on diagnostic knee arthroscopy in the OR
Study: NCT02130063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sucrose (Venofer®)
Study: NCT00779012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
Study: NCT03113981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Implanting THA grafted with PolyNass or not

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Implanting THA grafted with PolyNass or not
Study: NCT02718092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic Stent
Description: Subjects who are randomized to this arm will receive a plastic stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axios Fully Covered Self Expanding Metal Stent
Description: Subjects who are randomized to this arm will receive the Axios FCEMS
Study: NCT01397942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
Study: NCT01971385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Squaric Acid solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Study: NCT04079075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaption to memory loss
Description: This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnosis of hearing impairment
Description: Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
Study: NCT01546688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide at targeted daily doses of 100-500 mg/day
Description: Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administered to match targeted daily doses of 100-500 mg/day
Description: matching placebo
Study: NCT00648700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium Tablets 300 μg
Description: 2x300mcg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothroid® Tablets 300 μg
Description: 2x300mcg, single dose fasting